Brain N-acetylaspartate is reduced in Parkinson disease with dementia

被引:37
作者
Griffith, Henry Randall [1 ,2 ]
den Hollander, Jan A. [3 ]
Okonkwo, Ozioma C. [2 ]
O'Brien, Timothy [2 ]
Watts, Ray L. [1 ]
Marson, Daniel C. [1 ]
机构
[1] Univ Alabama Birmingham, Dept Neurol, Alzheimers Dis Res Ctr, Birmingham, AL 35294 USA
[2] Univ Alabama Birmingham, Dept Psychol, Alzheimers Dis Res Ctr, Birmingham, AL 35294 USA
[3] Univ Alabama Birmingham, Dept Med Cardiol, Alzheimers Dis Res Ctr, Birmingham, AL 35294 USA
关键词
Parkinson disease; MR spectroscopy; dementia; N-acetylaspartate; gyrus cinguli;
D O I
10.1097/WAD.0b013e3181611011
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Persons with Parkinson disease (PD) are at risk of developing dementia. Of the dementias affecting patients with PD. PD with dementia (PDD) is not well understood, although brain imaging studies to date have observed characteristic patterns of brain atrophy. Metabolic differences have been observed in magnetic resonance spectroscopy (MRS) studies comparing patients with PDD to nondemented PD patients, although it is unclear whether PDD patients have abnormally low MRS ratios compared with healthy age-matched adults. In this study, 12 patients with PDD, 12 patients with PD and no dementia. and 12 age-matched healthy older adults underwent MRS of the posterior cingulate gyrus. Patients with PDD showed lower N-acetylaspartate/creatine (NAA/Cr) compared with controls (P = 0.004) and compared with nondemented PD patients (P = 0.003). No abnormalities were observed in choline/Cr or myo-Inositol/Cr. NAA/Cr was correlated with mental status in patients with PD and in patients with PDD (r = 0.56; P = 0.029). The findings suggest that reduced NAA/Cr of the posterior cingulate could be used as a marker for dementia in patients with PD. Future studies investigating the utility of brain MRS as a predictor of dementia in PD and comparing brain metabolism in PDD with other dementias seem warranted.
引用
收藏
页码:54 / 60
页数:7
相关论文
共 47 条
[1]   Prevalence and characteristics of dementia in Parkinson disease - An 8-year prospective study [J].
Aarsland, D ;
Andersen, K ;
Larsen, JP ;
Lolk, A ;
Kragh-Sorensen, P .
ARCHIVES OF NEUROLOGY, 2003, 60 (03) :387-392
[2]  
Barkat M., 2005, Signal Detection and Estimation, V2nd
[3]  
BOWEN BC, 1995, AM J NEURORADIOL, V16, P61
[4]   Stages in the development of Parkinson's disease-related pathology [J].
Braak, H ;
Ghebremedhin, E ;
Rüb, U ;
Bratzke, H ;
Del Tredici, K .
CELL AND TISSUE RESEARCH, 2004, 318 (01) :121-134
[5]   Pattern of brain destruction in Parkinson's and Alzheimer's diseases [J].
Braak, H ;
Braak, E ;
Yilmazer, D ;
deVos, RAI ;
Jansen, ENH ;
Bohl, J .
JOURNAL OF NEURAL TRANSMISSION, 1996, 103 (04) :455-490
[6]   Imaging in Parkinson's disease: The role of monoamines in behavior [J].
Brooks, David J. ;
Piccini, Paola .
BIOLOGICAL PSYCHIATRY, 2006, 59 (10) :908-918
[7]   Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls [J].
Burton, EJ ;
McKeith, IG ;
Burn, DJ ;
Williams, ED ;
O'Brien, JT .
BRAIN, 2004, 127 :791-800
[8]   Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia [J].
Camicioli, RM ;
Korzan, JR ;
Foster, SL ;
Fisher, NJ ;
Emery, DJ ;
Bastos, AC ;
Hanstock, CC .
NEUROSCIENCE LETTERS, 2004, 354 (03) :177-180
[9]   Cramer-Rao bounds: an evaluation tool for quantitation [J].
Cavassila, S ;
Deval, S ;
Huegen, C ;
van Ormondt, D ;
Graveron-Demilly, D .
NMR IN BIOMEDICINE, 2001, 14 (04) :278-283
[10]   Magnetic resonance spectroscopy in Alzheimer's disease:: focus on N-acetylaspartate [J].
Chen, JG ;
Charles, HC ;
Barboriak, DP ;
Doraiswamy, PM .
ACTA NEUROLOGICA SCANDINAVICA, 2000, 102 :20-26